EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Biosimilar Candidate CT-P42 in Diabetic Macular Edema

Sebastian Wolf, Paulo-Eduardo Stanga, Milan Veselovsky, Miroslav Veith, Andras Papp, Shobhana Mange, Lakshmi Kanta Mondal, Dominika Romanczak, Ladislav Janco, Rohan Chauhan, Bożena Romanowska-Dixon, Alena Eremina und 10 weitere

Ophthalmology Retina · 2024

DOI: 10.1016/j.oret.2024.06.013 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Ophthalmology Retina, 2024. Verfasst von Sebastian Wolf und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Inselspital, Bern University Hospital, Bern, Switzerland; Department of BioMedical Research, Bern, Switzerland. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Diabetic Retinopathy, Macular Edema, Receptors, Vascular Endothelial Growth Factor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Celltrion Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsDiabetic RetinopathyMacular EdemaReceptors, Vascular Endothelial Growth FactorAgedFemaleHumansMaleMiddle AgedBiosimilar PharmaceuticalsDose-Response Relationship, DrugDouble-Blind MethodFollow-Up StudiesIntravitreal InjectionsMacula LuteaRecombinant Fusion ProteinsTime FactorsTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual Acuity

Stichwörter der Autor:innen

AfliberceptBiosimilarCT-P42Diabetic macular edema

Substanzen

afliberceptAngiogenesis InhibitorsBiosimilar PharmaceuticalsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Inselspital, Bern University Hospital, Bern, Switzerland; Department of BioMedical Research, Bern, Switzerland.
  • The Retina Clinic London, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
  • Faculty hospital with Policlinic Zilina, Ophthalmology Department, Zilina, Slovakia.
  • Univerzity Hospital Kralovske Vinohrady, Prague, Czech Republic; 3(rd) Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Semmelweis University Department of Ophthalmology, Budapest, Hungary.
  • Shivam Retina Clinic and Eye Hospital, Surat, India.

Förderung

  • Celltrion Inc

Zitieren

APA

Wolf, S., Stanga, P. E., Veselovsky, M., Veith, M., Papp, A., Mange, S., Kanta Mondal, L., Romanczak, D., Janco, L., Chauhan, R., Romanowska-Dixon, B., Eremina, A., Zavgorodnya, N., Dusova, J., Sagong, M., Kim, S., Ahn, K., Kim, S., Bae, Y., …, & Brown, D. M. (2024). Biosimilar Candidate CT-P42 in Diabetic Macular Edema. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2024.06.013

Vancouver

Wolf S, Stanga PE, Veselovsky M, Veith M, Papp A, Mange S, et al. Biosimilar Candidate CT-P42 in Diabetic Macular Edema. Ophthalmology Retina. 2024. doi:10.1016/j.oret.2024.06.013

BibTeX
@article{Wolf2024,
  author = {Wolf, Sebastian and Stanga, Paulo-Eduardo and Veselovsky, Milan and Veith, Miroslav and Papp, Andras and Mange, Shobhana and Kanta Mondal, Lakshmi and Romanczak, Dominika and Janco, Ladislav and Chauhan, Rohan and Romanowska-Dixon, Bożena and Eremina, Alena and Zavgorodnya, Nataliya and Dusova, Jaroslava and Sagong, Min and Kim, Sunghyun and Ahn, Keumyoung and Kim, Suyoung and Bae, Youngmin and Lee, Sangmi and Kang, Hyejin and Brown, David M},
  title = {Biosimilar Candidate CT-P42 in Diabetic Macular Edema},
  journal = {Ophthalmology Retina},
  year = {2024},
  doi = {10.1016/j.oret.2024.06.013}
}
Kostenlos starten →